Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 4/2016

01-12-2016 | Case Report

Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule

Authors: Nishikant Avinash Damle, Madhavi Tripathi, Partha Sarathi Chakraborty, Manas Kumar Sahoo, Chandrasekhar Bal, Shipra Aggarwal, Geetanjali Arora, Praveen Kumar, Rajeev Kumar, Ravikant Gupta

Published in: Nuclear Medicine and Molecular Imaging | Issue 4/2016

Login to get access

Abstract

68Ga-Prostate specific membrane antigen- N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid- positron emission tomography/computed tomography or 68 Ga- HBED-CC-PSMA PET/CT, popularly known as PSMA PET/CT, is able to detect a small volume of recurrent prostate carcinoma (PC) when there is a prostate specific antigen (PSA) rise on follow-up after prostatectomy or other definitive treatment for PC. The use of PSMA PET/CT in the initial staging in PC is uncertain at this time. Clinical studies are underway to define its exact role in the management of the disease. At the same time it is important to be aware of unexpected sites of uptake of this ligand. We present here the case of a 62-year-old male patient who underwent prostatectomy for adenocarcinoma prostate. He also had a long-standing left solitary thyroid nodule (STN). Four months after surgery, he had a rising trend in serum PSA levels on three occasions, but the absolute value was less than 4 at all times. He underwent a 68Ga-PSMA-HBED-CC PET/CT, but it did not reveal any recurrent/metastatic site of disease. However, there was increased tracer uptake in the left STN. Fine needle aspiration cytology revealed features of atypia of undetermined significance, Bethesda category III. The patient underwent a left hemithyroidectomy and the histopathology showed features of a follicular adenoma.
Literature
1.
go back to reference Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2:23.CrossRefPubMedPubMedCentral Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2:23.CrossRefPubMedPubMedCentral
2.
go back to reference Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, et al. Novel preclinical and radiopharmaceutical aspects of 68Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals. 2014;7:779–96.CrossRefPubMedPubMedCentral Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, et al. Novel preclinical and radiopharmaceutical aspects of 68Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals. 2014;7:779–96.CrossRefPubMedPubMedCentral
4.
go back to reference Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.PubMed Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.PubMed
5.
go back to reference Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003;100:12590–5.CrossRefPubMedPubMedCentral Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003;100:12590–5.CrossRefPubMedPubMedCentral
6.
go back to reference Hellwig D, Moosbauer J, Eilles C. 68Ga-PSMA PET/CT for prostate cancer. Aktuelle Urol. 2014;45:457–63.CrossRefPubMed Hellwig D, Moosbauer J, Eilles C. 68Ga-PSMA PET/CT for prostate cancer. Aktuelle Urol. 2014;45:457–63.CrossRefPubMed
7.
go back to reference Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40:163–6.CrossRef Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40:163–6.CrossRef
8.
go back to reference Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep. 2010;11:180–90.CrossRefPubMedPubMedCentral Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep. 2010;11:180–90.CrossRefPubMedPubMedCentral
9.
go back to reference Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. 68Ga-Gallium-labelled PSMA ligand as superior PET tracer for diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6.CrossRefPubMed Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. 68Ga-Gallium-labelled PSMA ligand as superior PET tracer for diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6.CrossRefPubMed
10.
go back to reference Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a 68Ga-gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefPubMed Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a 68Ga-gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefPubMed
11.
go back to reference Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. 68Ga-PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.CrossRefPubMed Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. 68Ga-PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.CrossRefPubMed
12.
go back to reference Brindle R, Mullan D, Yap BK, Gandhi A. Thyroid incidentalomas discovered on positron emission tomography CT scanning—Malignancy rate and significance of standardised uptake values. Eur J Surg Oncol. 2014;40:1528–32.CrossRefPubMed Brindle R, Mullan D, Yap BK, Gandhi A. Thyroid incidentalomas discovered on positron emission tomography CT scanning—Malignancy rate and significance of standardised uptake values. Eur J Surg Oncol. 2014;40:1528–32.CrossRefPubMed
13.
go back to reference Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3.CrossRefPubMed Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3.CrossRefPubMed
14.
go back to reference Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, et al. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2.CrossRefPubMed Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, et al. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2.CrossRefPubMed
15.
go back to reference Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMed Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMed
Metadata
Title
Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule
Authors
Nishikant Avinash Damle
Madhavi Tripathi
Partha Sarathi Chakraborty
Manas Kumar Sahoo
Chandrasekhar Bal
Shipra Aggarwal
Geetanjali Arora
Praveen Kumar
Rajeev Kumar
Ravikant Gupta
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 4/2016
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0408-y

Other articles of this Issue 4/2016

Nuclear Medicine and Molecular Imaging 4/2016 Go to the issue